Oncology Data Advisor™ · Investigating Brentuximab Vedotin for Advanced-Stage Hodgkin Lymphoma With Habte Yimer, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Habte Yimer of Texas Oncology sat down with Oncology Data Advisor to elaborate on the promising results of brentuximab vedotin for patients with advanced-stage classical Hodgkin lymphoma, including the most recent data and future directions for the trial.  

Oncology Data Advisor™ · Investigating Momelotinib for Treatment of Myelofibrosis With Srdan Verstovsek, MD, PhD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Srdan Verstovsek, Chief of the Section for Myeloproliferative Neoplasms in the Department of Leukemia at MD Anderson Cancer Center, sat down to discuss h...

Oncology Data Advisor™ · Describing Real-World Treatment Patterns for Myelodysplastic Syndromes With Ira Zackon, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Ira Zackon sat down with Oncology Data Advisor to discuss his abstract regarding real-world treatment patterns and survival outcomes among patients with myelodysplastic syndromes (MDS), including ways for making clinical trial data applicable for patients treated in the community oncology setting.  

Oncology Data Advisor™ · Subsequent Treatment After CAR T-Cell Therapy in Large B-Cell Lymphoma With Armin Ghobadi, MD Recently, at the American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Armin Ghobadi, an Associate Professor at the Washington University School of Medicine, Siteman Cancer Center, sat down with Oncol...

Oncology Data Advisor™ · Optimizing Patient Outcomes With CAR T-Cell Therapy With Ola Oluwole, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Ola Oluwole of Vanderbilt University Medical Center, sat down with Oncology Data Advisor to discuss two of his abstracts on prophylactic corticosteroid use for patients receiving axicabtagene ciloleucel and the role of cytokine release syndrome in the efficacy of chimeric antigen receptor (CAR) T-cell therapy.  

Oncology Data Advisor™ · Improving the Standard of Care for Advanced Hodgkin Lymphoma With Mitul Gandhi, MD At the recent American Society of Hematology (ASH) Annual Meeting, updated results were presented for the SGN35-027 study of brentuximab vedotin plus nivolumab and chemotherapy for advanced-stage classical Hodgkin lymphoma. One of its authors, Dr. Mitul Gandhi of Virginia Cancer Specialists, sat down with Oncology Data Advisor while there to discuss the importance of the trial's results and the next steps for improving upon the standard of care for advanced Hodgkin lymphoma.  

Oncology Data Advisor™ · Updates on Trials of Zilovertamab and Brentuximab Vedotin in Lymphomas With Hun Lee, MD At the recent American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor met with Dr. Hun Lee of MD Anderson to discuss the two abstracts that he presented there. Dr. Lee provided an update on the promising data for zilovertamab plus ibrutinib for patients with mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL), and for brentuximab vedotin plus nivolumab and chemotherapy for patients with Hodgkin lymphoma.  

Oncology Data Advisor™ · Association of Socioeconomic Status With Adherence and Survival in Myeloma: Leon Bernal-Mizrachi, MD At the recent American Society of Hematology (ASH) Annual Meeting in New Orleans, Leon Bernal-Mizrachi, MD, an Associate Professor of Medicine in the Department of Hematology and Oncology at the Emory University...

Oncology Data Advisor™ · Advancing the Careers of Women in Hematology With Ariela Marshall, MD At the recent American Society of Hematology (ASH) Annual Meeting, Ariela Marshall, MD, Director of the Women's Hemostasis and Thrombosis Program and Associate Professor of Clinical Medicine at Penn Medicine, sat down with Oncology Data Advisor to talk about the ASH Women in Hematology Working Group, a group committed to career advances and leadership opportunities for women in hematology.  

Oncology Data Advisor™ · Factors Leading to Black Patient Disparities in Hematology Trials With Shakira Grant, MBBS At the recent American Society of Hematology (ASH) Annual Meeting, Shakira J. Grant, MBBS, an Assistant Professor of Medicine at the University of North Carolina at Chapel Hill, sat down with Oncology Data Advisor to discuss her research she presented, "If You Don't Trust Your Doctor That Much…You'd Feel Less Confident Doing a Research Study": Factors Influencing Black Patient Participation in Hematology Trials.

Oncology Data Advisor™ · Making Health Care Accessible for Acute Myeloid Leukemia Patients With Ian Bouligny, MD At the 2022 American Society of Hematology (ASH) Annual Meeting, Dr. Ian Bouligny, Hematology/Oncology Fellow at Virginia Commonwealth University (VCU) Massey Cancer Center, spoke with Oncology Data Advisor about his abstract regarding health care disparities faced by Black patients with acute myeloid leukemia (AML). Dr. Bouligny explains the factors that contribute to treatment disparities and shares strategies for equalizing health care accessibility on both the local and the national levels.  

Oncology Data Advisor™ · Creating Valuable Education for the Hematology/Oncology Fellow: Ronak Mistry and Vivek Patel At the 2022 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor sat down with Dr. Ronak Mistry and Dr. Vivek Patel, Clinical Fellows in Medicine at Vanderbilt University and hosts of The Fellow on Call podcast. Dr. Mistry and Dr. Patel share their passion for creating education geared towards fellows and the valuable experience of attending ASH as a trainee.  

Oncology Data Advisor™ · Dynamic Risk Classification of Smoldering Myeloma With Luis Gerardo Rodríguez-Lobato, MD, PhD At the recent American Society of Hematology (ASH) Annual Meeting, Luis Gerardo Rodríguez-Lobato, MD, PhD, Specialist in Hematopoietic Stem Cell Transplant and Researcher at the Hospital Clínic de Barcelona and barnaclínic+, sat down with Oncology Data Advisor to discuss his research regarding dynamic risk classification for patients with smoldering multiple myeloma and how such a strategy can help clinicians predict the course of disease.  

Oncology Data Advisor™ · Understanding Multiple Myeloma Treatment Patterns and Sequencing With Robert Rifkin, MD At the recent 64th American Society of Hematology (ASH) Annual Meeting, Dr. Robert Rifkin, Medical Oncologist and Hematologist at Rocky Mountain Cancer Centers in Denver, Colorado, sat down with Oncology Data Advisor to discuss the research that he presented, titled Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry.  

Oncology Data Advisor™ · Exploring the Results of Elranatamab for Relapsed/Refractory Multiple Myeloma With Noopur Raje, MD Recently, Dr. Noopur Raje, Director of the Center for Multiple Myeloma at Massachusetts General Hospital, sat down with Oncology Data Advisor at the 64th American Society of Hematology (ASH) Annual Meeting to disc...

Oncology Data Advisor™ · Investigating CAR T Wait Time and High-Risk Myeloma Definitions With Samer Al Hadidi, MD, MS, FACP At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Samer Al Hadidi, Assistant Professor at the University of Arkansas, sat down with Oncology Data Advisor to discuss the multiple myeloma research that he presented. Dr. Al Hadidi elaborates on his studies regarding the wait list for patients who are eligible to receive chimeric antigen receptor (CAR) T-cell therapy and the variability of definitions of high-risk disease in myeloma clinical trials.  

Oncology Data Advisor™ · Studying the Promising Role of Bispecific Antibodies in Multiple Myeloma With Ajai Chari, MD At the recent American Society of Hematology (ASH) Annual Meeting, Ajai Chari, MD, the Director of Research in the Multiple Myeloma Program at the Icahn School of Medicine at Mount Sinai, New York, sat down with Oncology Data Advisor to discuss his presentation regarding the phase 1/2 results of the MonumenTAL-1 study. This study researches the possible benefit of talquetamab, a bispecific antibody, in patients with relapsed or refractory multiple myeloma.  

Oncology Data Advisor™ · Investigating the Efficacy of HPN217 in Relapsed/Refractory Multiple Myeloma With Luke Walker, MD At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Luke Walker, Chief Medical Officer of Harpoon Therapeutics, sat down with Oncology Data Advisor to discuss the results of a phase 1 trial of HPN217, a B-cell maturation antigen (BCMA)–targeting T-cell engager, which were presented at the meeting. Dr. Walker delves into the efficacy that HPN217 demonstrated in patients with relapsed/refractory multiple myeloma, including its tolerability and low risk of cytokine release syndrome (CRS).  

Oncology Data Advisor™ · Discussing the Relevance of Urine Studies in Myeloma With Kelsey Natsuhara, MD At the recent American Society of Hematology (ASH) Annual Meeting, Kelsey Natsuhara, MD, a Fellow in Hematology and Oncology at the University of California, San Francisco, sat down with Oncology Data Advisor and ConveyMED to discuss...

Oncology Data Advisor™ · ASH 2022 Conversations on Multiple Myeloma (Part 1) With Manni Mohyuddin, MBBS At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Manni Mohyuddin, Assistant Professor at the University of Utah Huntsman Cancer Institute, sat down with Oncology Data Advisor to discuss the multiple myeloma research he was involved with at this year's meeting. Dr. Mohyuddin elaborates on his abstracts regarding the prognostic value of (11;14) translocation in multiple myeloma, the characterization of survival end points in clinical trials, and ways to improve the quality of news reporting of oncology clinical trials.